Thermo Fisher Scientific CD279 (PD-1) Monoclonal Antibody (eBioJ105 (J105)), eBioscience

Applications

Tested Dilution

Publications

Immunohistochemistry (IHC)

-

View 2 publications 2 publications

Immunohistochemistry (Frozen) (IHC (F))

Assay-Dependent

View 2 publications 2 publications

Immunocytochemistry (ICC/IF)

-

View 1 publication 1 publication

Flow Cytometry (Flow)

1 µg/test

View 32 publications 32 publications

ELISA (ELISA)

-

View 1 publication 1 publication

Immunoprecipitation (IP)

Assay-Dependent

-

Product Specifications

Species Reactivity

Human, Rhesus monkey

Published species

Baboon, Human, Mouse, Non-human primate, Rhesus monkey

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

eBioJ105 (J105)

Conjugate

Unconjugated Unconjugated Unconjugated

View additional formats

• APC
• APC-eFluor 780
• Biotin
• Brilliant UV 615
• Brilliant UV 661
• Brilliant UV 737
• Brilliant UV 805
• Brilliant Violet 421
• Brilliant Violet 480
• Brilliant Violet 650
• Brilliant Violet 711
• Brilliant Violet 786
• PE
• PE-Cyanine5
• PE-Cyanine7
• PE-eFluor 610
• PerCP-eFluor 710
• Super Bright 436
• Super Bright 600
• Super Bright 645
• Super Bright 702
• Super Bright 780
• Request custom conjugation

Form

Liquid

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2865049

Product Specific Information

Description: The J105 monoclonal antibody reacts with the human PD-1 (programmed death-1), a 55 kDa member of the CD28 immunoglobulin superfamily. PD-1 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) and plays a key role in peripheral tolerance and autoimmune disease. PD-1 is expressed predominantly on activated T and B lymphocytes. Two novel members of the B7 family have been identified as the PD-1 ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC). Evidence reported to date suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells.

Costaining experiments suggest that eBioJ105 recognizes a different epitope than MIH4 (Product # 11-9969).

Applications Reported: This eBioJ105 (J105) antibody has been reported for use in flow cytometric analysis, immunoprecipitation, and immunohistology staining of frozen tissue sections.

Applications Tested: This eBioJ105 (J105) antibody has been tested by flow cytometic analysis of PHA stimulated normal human peripheral blood cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of danger signals such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1- mice who exhibit hyperactivated immune systems and autoimmune diseases. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.